XML 54 R43.htm IDEA: XBRL DOCUMENT v3.21.2
Fair value of financial instruments and marketable securities - Narrative (Details)
1 Months Ended 3 Months Ended 9 Months Ended
Aug. 31, 2021
USD ($)
Feb. 28, 2021
USD ($)
fund
$ / shares
Jan. 31, 2020
USD ($)
$ / shares
Sep. 30, 2021
USD ($)
Sep. 30, 2020
USD ($)
Sep. 30, 2021
USD ($)
Sep. 30, 2020
USD ($)
shares
Dec. 31, 2020
USD ($)
Apr. 29, 2020
Sep. 30, 2019
USD ($)
$ / shares
May 31, 2019
USD ($)
$ / shares
Aug. 31, 2015
USD ($)
$ / shares
Financial assets and liabilities measured at fair value on recurring basis                        
Write downs of available for sale debt securities       $ 0   $ 0            
Realized gain (loss) from sale of marketable securities       0.0 $ 300,000 700,000 $ 500,000          
Increase in allowance for credit losses       0 0 0 0          
Unrealized gain (loss) on ClearPoint Equity Investment       (1,700,000) 2,500,000 2,376,000 852,000          
Marketable securities - equity investments       23,000,000.0   23,000,000.0   $ 20,500,000        
Purchase of convertible debt investment     $ 10,000,000.0       10,000,000          
Conversion price per share (in dollars per share) | $ / shares     $ 6.00                  
Debt instrument, convertible, period     5 years                  
Unrealized loss       2,300,000     600,000          
Unrealized gain on convertible note         1,400,000 2,100,000            
Fair value of convertible debt       31,300,000   31,300,000   29,300,000        
Purchase of marketable securities - equity investments $ 5,400,000 $ 200,000,000.0       205,382,000            
Number of mutual funds invested in | fund   2                    
Redemption of marketable securities- equity investments       700,000   740,000            
Unrealized gain on marketable securities - equity investments       700,000   1,400,000            
Unrealized foreign currency losses on equity investments       200,000   200,000            
Transfers of assets measured between Level 1, Level 2, and Level 3       0   0   0        
Non-cash stock consideration, acquisition             42,869,000          
Operating Expenses       231,819,000 173,535,000 663,077,000 597,296,000          
Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Asset       (10,800,000) $ (8,400,000) (11,600,000) $ (16,980,000)          
Common stock                        
Financial assets and liabilities measured at fair value on recurring basis                        
Issuance of common stock related to rights exchange (in shares) | shares             2,821,176          
3.00% Convertible senior notes due 2022 | Convertible debt                        
Financial assets and liabilities measured at fair value on recurring basis                        
Principal       150,000,000   150,000,000   150,000,000       $ 150,000,000.0
Interest rate ( as a percent )                       3.00%
Fair value of convertible notes       155,500,000   155,500,000   193,200,000        
Conversion price per share (in dollars per share) | $ / shares                       $ 56.34
1.50% Convertible senior notes due 2026 | Convertible debt                        
Financial assets and liabilities measured at fair value on recurring basis                        
Principal       $ 287,500,000   $ 287,500,000   287,500,000   $ 287,500,000    
Interest rate ( as a percent )       1.50%   1.50%       1.50%    
Fair value of convertible notes       $ 294,900,000   $ 294,900,000   394,900,000        
Conversion price per share (in dollars per share) | $ / shares                   $ 52.52    
Agilis                        
Financial assets and liabilities measured at fair value on recurring basis                        
Development milestone payments which the entity is obligated to pay       $ 40,000,000.0   $ 40,000,000.0            
Agilis | Minimum                        
Financial assets and liabilities measured at fair value on recurring basis                        
Product sales (as a percent)       2.00%   2.00%     2.00%      
Agilis | Maximum                        
Financial assets and liabilities measured at fair value on recurring basis                        
Product sales (as a percent)       6.00%   6.00%     6.00%      
Development milestone payments which the entity is obligated to pay       $ 60,000,000.0   $ 60,000,000.0            
Priority review voucher amount           535,000,000.0            
Net sales amount       150,000,000.0   150,000,000.0            
Recurring basis                        
Financial assets and liabilities measured at fair value on recurring basis                        
Fair value of convertible debt       $ 31,306,000   $ 31,306,000   $ 29,252,000        
Common stock                        
Financial assets and liabilities measured at fair value on recurring basis                        
Shares purchased   $ 100,000                 $ 4,000,000.0  
Share price (in USD per share) | $ / shares   $ 23.50                 $ 3.10  
Development and Regulatory Milestone | Probability of Success | Weighted Average | Contingent Consideration Payable                        
Financial assets and liabilities measured at fair value on recurring basis                        
Rights Exchange settlement       42   42            
Development and Regulatory Milestone | Agilis | Measurement Input, Discount Rate | Weighted Average | Contingent Consideration Payable                        
Financial assets and liabilities measured at fair value on recurring basis                        
Rights Exchange settlement       3.3   3.3            
Net Sales Milestones and Royalties | Probability of Success | Weighted Average | Contingent Consideration Payable                        
Financial assets and liabilities measured at fair value on recurring basis                        
Rights Exchange settlement       48   48            
Net Sales Milestones and Royalties | Agilis | Measurement Input, Discount Rate | Contingent Consideration Payable                        
Financial assets and liabilities measured at fair value on recurring basis                        
Rights Exchange settlement       0.110   0.110